Zura Bio (ZURA) Price & Analysis

Compare

462 Followers

ZURA Stock Chart & Stats

$4.27

-$0.21(-8.71%)

At close: Jan 08 4:00 PM EST

$4.27

-$0.21(-8.71%)

Day’s Range― - ―

52-Week Range$0.97 - $4.68

Previous CloseN/A

Volume136.30K

Average Volume (3M)2.99M

Market Cap

$278.30M

Enterprise Value-$42.28M

Total Cash (Recent Filing)$139.02M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta1.52

Next Earnings

Apr 01, 2026

EPS Estimate

-0.2

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.21

Shares Outstanding65,023,310

10 Day Avg. Volume1,304,161

30 Day Avg. Volume2,987,270

Financial Highlights & Ratios

PEG Ratio0.06

Price to Book (P/B)1.28

Price to Sales (P/S)0.00

P/FCF Ratio-6.67

Enterprise Value/Market Cap-0.15

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit1.69K

Enterprise Value/Ebitda0.61

Forecast

1Y Price Target

$16.50

Price Target Upside286.42% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Bears Say

Clinical Data ConcernsThe initiation of the Phase 2 study for tibulizumab in hidradenitis suppurativa raises questions due to past lackluster clinical data and no clear dose-dependent response.

Combination Therapy SkepticismSkepticism exists regarding the advantage of combining an IL-17A-only inhibitor with a BAFF inhibitor in the treatment of HS, particularly given the competition from more effective dual IL-17A/F inhibitors.

Competitive Market ChallengesThe market for HS treatment is increasingly competitive, with dual IL-17A/F inhibitors showing impressive efficacy and setting a high benchmark that could overshadow older treatments like tibulizumab.

Zura Bio News

Zura Bio Director Resignation Sparks Governance Adjustments

Zura Bio ( ($ZURA) ) has issued an update. On December 11, 2025, Arnout Ploos van Amstel resigned...

3d ago

ZURA

Zura Bio Limited Reports Third Quarter 2025 Results

Zura Bio Limited ( ($ZURA) ) has released its Q3 earnings. Here is a breakdown of the information...

1M ago

ZURA

Zura Bio reports Q3 EPS (21c), consensus (18c)

Reported $139.0M in cash and cash equivalents as of September 30, expected to fund planned operations through 2027....

1M ago

ZURA

Zura Bio initiated with a Buy at Clear Street

Clear Street initiated coverage of Zura Bio (ZURA) with a Buy rating and $18 price target The firm...

1M ago

ZURA

Zura Bio’s Promising Phase 2 Study on Tibulizumab for Systemic Sclerosis

Zura Bio Limited (($ZURA)) announced an update on their ongoing clinical study. Zura Bio Limited is currently conducting...

2M ago

ZURA

Zura Bio’s Promising Phase 2 Study on Tibulizumab for Hidradenitis Suppurativa

Zura Bio Limited (($ZURA)) announced an update on their ongoing clinical study. Study Overview: Zura Bio Limited is...

2M ago

ZURA

Zura Bio CEO Takes Medical Leave, Interim Appointed

Zura Bio ( ($ZURA) ) has issued an announcement. On October 8, 2025, Zura Bio Limited announced that...

2M ago

ZURA

Zura Bio Implements Executive Severance Benefit Plan

Zura Bio ( ($ZURA) ) has issued an update. On September 24, 2025, Zura Bio Limited’s Board of...

3M ago

ZURA

Zura Bio Unveils Updated Corporate Presentation

Zura Bio ( ($ZURA) ) just unveiled an announcement. On September 4, 2025, Zura Bio Limited announced an...

4M ago

ZURA

Zura Bio to Attend Global Healthcare Conference

An announcement from Zura Bio ( ($ZURA) ) is now available. On August 20, 2025, Zura Bio announced...

4M ago

ZURA

Zura Bio price target lowered to $2 from $3 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Zura Bio (ZURA) to $2 from $3 and keeps a...

4M ago

ZURA

Zura Bio price target lowered to $16 from $17 at Oppenheimer

Oppenheimer lowered the firm’s price target on Zura Bio (ZURA) to $16 from $17 and keeps an Outperform...

4M ago

ZURA

Zura Bio Limited Reports Q2 2025 Financial Results

Zura Bio Limited ( ($ZURA) ) has released its Q2 earnings. Here is a breakdown of the information...

4M ago

ZURA

Novartis trial has positive read for Zura Bio, says Guggenheim

After Novartis (NVS) announced that both of two Phase 3 trials evaluating ianalumab in adults with active Sjogren’s...

4M ago

NVS

ZURA

ZURA FAQ

What was Zura Bio’s price range in the past 12 months?

Zura Bio lowest stock price was $0.97 and its highest was $4.68 in the past 12 months.

What is Zura Bio’s market cap?

Zura Bio’s market cap is $278.30M.

When is Zura Bio’s upcoming earnings report date?

Zura Bio’s upcoming earnings report date is Apr 01, 2026 which is in 102 days.

How were Zura Bio’s earnings last quarter?

Zura Bio released its earnings results on Nov 13, 2025. The company reported -$0.21 earnings per share for the quarter, missing the consensus estimate of -$0.191 by -$0.019.

Is Zura Bio overvalued?

According to Wall Street analysts Zura Bio’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Zura Bio pay dividends?

Zura Bio does not currently pay dividends.

What is Zura Bio’s EPS estimate?

Zura Bio’s EPS estimate is -0.2.

How many shares outstanding does Zura Bio have?

Zura Bio has 65,023,310 shares outstanding.

What happened to Zura Bio’s price movement after its last earnings report?

Zura Bio reported an EPS of -$0.21 in its last earnings report, missing expectations of -$0.191. Following the earnings report the stock price went down -9.719%.

Which hedge fund is a major shareholder of Zura Bio?

Currently, no hedge funds are holding shares in ZURA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Zura Bio Stock Smart Score

Outperform

Fundamentals

Return on Equity

-47.85%

Trailing 12-Months

Asset Growth

-16.73%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.

Zura Bio (ZURA) Earnings & Revenues

Historic Earnings Reports

ZURA Stock 12 Month Forecast

Average Price Target

$16.50

▲(286.42% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","19":"$19","4.75":"$4.75","9.5":"$9.5","14.25":"$14.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$18.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$16.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$15.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,4.75,9.5,14.25,19],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Apr<br/>2025","9":"Aug<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.72,4.818461538461539,5.9169230769230765,7.015384615384615,8.113846153846154,9.212307692307693,10.31076923076923,11.409230769230769,12.507692307692308,13.606153846153846,14.704615384615385,15.803076923076922,16.90153846153846,{"y":18,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.72,4.703076923076924,5.686153846153847,6.6692307692307695,7.6523076923076925,8.635384615384616,9.618461538461538,10.601538461538462,11.584615384615384,12.567692307692308,13.550769230769232,14.533846153846154,15.516923076923078,{"y":16.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.72,4.587692307692308,5.455384615384616,6.323076923076924,7.190769230769231,8.058461538461538,8.926153846153847,9.793846153846154,10.661538461538461,11.52923076923077,12.396923076923077,13.264615384615384,14.132307692307693,{"y":15,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.13,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.85,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.38,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.8,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.5,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.36,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.18,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.47,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.05,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.5,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.02,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.84,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.72,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >